The up-regulation of PAK2 indicates unfavorable prognosis in patients with serous epithelial ovarian cancer and contributes to paclitaxel resistance in ovarian cancer cells
PAK2 shows promise as a predictor of chemotherapy resistance and poor outcomes in ovarian cancer, indicating its potential use as a treatment target to overcome this resistance.
Authors
- Ting Shuang (ORCID: https://orcid.org/0000-0002-6119-6989)
- Meili Pei (ORCID: https://orcid.org/0009-0003-9170-5320)
- Yifei Zhao (ORCID: https://orcid.org/0009-0002-7785-6774)
- Shiyun Wu (ORCID: https://orcid.org/0009-0004-2952-4606)
- Yanqi Yang
Institutions
- First Affiliated Hospital of Xi'an Jiaotong University (CN)
- Xi'an Jiaotong University (CN)
Publication Details
- Journal
- BMC Cancer
- Published
- 2024-09-30
- DOI
- https://doi.org/10.1186/s12885-024-12969-1
- Citations
- 8
- Primary Topic
- Ovarian cancer diagnosis and treatment
- Type
- article
- Field-Weighted Citation Impact
- 4.30
Funders
- National Natural Science Foundation of China
- Yakult Bio-Science Foundation
- Key Research and Development Projects of Shaanxi Province